icometrix vs TeraRecon
Perfusion is the shared ground. icometrix's icobrain-ctp (K192962, February 28, 2020) is CT perfusion. TeraRecon's Neuro.AI (K200750, November 6, 2020) and TeraRecon Neuro (K220349, August 12, 2022) are cleared for CT and MRI perfusion analysis, all three under code LLZ. A neuro-imaging department that wants perfusion on both modalities, plus cardiac MR and aorta tools such as Cardiac.Chambers.MR (K241312) and Aorta.CT (K243158) from the same vendor, should take TeraRecon, and icometrix is the narrower choice there.
icometrix is the pick for ARIA monitoring and brain MRI follow-up. Its icobrain aria record is K240712 of November 7, 2024, code QBS. GE HealthCare announced on September 10, 2025 that it would acquire icometrix, terms undisclosed.
TeraRecon now brands itself ConcertAI's TeraRecon and claims more than 2,000 hospitals. Its platform hosts other vendors' algorithms and passes results over DICOM and HL7.
Radiology · Reviewed November 2, 2026
icometrix
by icometrix NV · founded 2011
FDA-cleared icobrain AI quantifies brain structures and lesions on MRI and CT and tracks changes over time.
TeraRecon
by ConcertAI · founded 1997
Advanced CT and MR visualization with cardiac, aorta and neuro AI, plus a vendor-agnostic platform to run third-party AI.
When to pick each one
icometrix
- ARIA detection for anti-amyloid monitoring, K240712
- GE HealthCare agreed to acquire it, September 2025
TeraRecon
- CT and MRI perfusion, Neuro.AI K200750
- Cardiac MR and aorta CT tools
- Hosts third-party AI over DICOM and HL7
Score
Each row shows points earned of points available under the published rubric.
icometrix
68of 100
TeraRecon
42of 100
| Dimension | icometrix | TeraRecon | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 18.2 / 18.2 | 0 / 18.2 | +18.2 |
| RCT / meta-analysis / systematic review | 3.9 / 7.8 | 0 / 7.8 | +3.9 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 6 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
icometrix
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
TeraRecon
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
icometrix
FDA decisions
K240712 (opens in new tab)510(k)2024-11-07
icobrain aria
K192962 (opens in new tab)510(k)2020-02-28
icobrain-ctp
K192130 (opens in new tab)510(k)2019-12-13
Icobrain
K181939 (opens in new tab)510(k)2018-11-06
icobrain
K180326 (opens in new tab)510(k)2018-03-08
icobrain
Show 1 more
K161148 (opens in new tab)510(k)2016-08-09
icobrain
Peer-reviewed
5 PubMed records name icometrix.
- Lecanemab in practice: AI-derived MRI predictors of benefit and Amyloid Related Imaging Abnormalities (ARIA). (opens in new tab)
- Uncovering heterogeneous cognitive trajectories in relapsing-remitting multiple sclerosis: a longitudinal study. (opens in new tab)
- Quantifying White Matter Hyperintensities: Automated Volumetry Compared with Visual Grading Scales. (opens in new tab)
TeraRecon
FDA decisions
K250288 (opens in new tab)510(k)2025-10-23
TeraRecon Cardiovascular.Calcification.CT
K243158 (opens in new tab)510(k)2025-01-23
TeraRecon Aorta.CT (1.1.0)
K241312 (opens in new tab)510(k)2024-11-05
TeraRecon Cardiac.Chambers.MR (1.0.0)
K220349 (opens in new tab)510(k)2022-08-12
TeraRecon Neuro
K200750 (opens in new tab)510(k)2020-11-06
Neuro.AI Algorithm
Show 2 more
K191585 (opens in new tab)510(k)2019-07-12
iNtuition-Structural Heart Module
K180916 (opens in new tab)510(k)2018-09-24
iNtuition-T1 Mapping and T2/T2* Mapping
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | icometrix | TeraRecon |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2011 | 1997 |
| HQ | BE | US |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.